ClinicalTrials.gg

Program

tucatinib

Also written as “Tucatinib”, “Tucatinib (ONT-380)” and “ARRY-380, HER2 inhibitor; oral”.

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasms, led by 4 companies.

Furthest: phase 4, since Aug 12, 202625 company-led studies, 11 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer218 open or runningphase 4since Aug 12, 2026Mar 31, 2008Dec 31, 2026phase 1 · NCT05382364
Criterium22 open or runningphase 2since Dec 27, 2021Dec 27, 2021Jun 1, 2027phase 2 · NCT05458674
AstraZeneca11 open or runningphase 2since Aug 31, 2020Aug 31, 2020none ahead
Hoffmann-La Roche10 open or runningphase 2since Nov 12, 2020Nov 12, 2020none ahead

Also a collaborator on its studies: Novartis.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Mar 31, 2008.

  1. Jun 4, 2019Phase 3 study in HER2-positive Breast CancerPfizer · NCT03975647 · 466 enrolled · United States, Australia, Austria and more
  2. Jun 10, 2020Phase 2 study in Colorectal NeoplasmsPfizer · NCT04430738 · 40 enrolled · United States, Japan
  3. Jul 31, 2020Phase 3 study in Adenocarcinoma Of EsophagusPfizer · NCT04499924 · 17 enrolled · United States, Australia, Canada and more
  4. Aug 31, 2020Phase 2 study in Breast NeoplasmsPfizer · NCT04539938 · 70 enrolled · United States
  5. Aug 31, 2020AstraZeneca's first study: phase 2 study in Breast NeoplasmsNew to AstraZenecaAstraZeneca · NCT04538742 · 245 enrolled · United States, Australia, Brazil and more
  6. Oct 1, 2020Phase 2 study in Uterine NeoplasmsPfizer · NCT04579380 · 217 enrolled · United States, Belgium, Germany and more
  7. Nov 12, 2020Hoffmann-La Roche's first study: phase 2 study in Advanced Unresectable or Metastatic Solid MalignancyNew to Hoffmann-La RocheHoffmann-La Roche · NCT04632992 · 252 enrolled · United States
  8. Jan 20, 2021Phase 2 study in Breast NeoplasmsPfizer · NCT04721977 · 66 enrolled · Japan, South Korea, Taiwan
  9. Nov 12, 2021Phase 3 study in Breast NeoplasmsPfizer · NCT05132582 · 654 enrolled · United States, Australia, Austria and more
  10. Dec 27, 2021Criterium's first study: phase 2 study in HER2-positive Metastatic Breast CancerNew to CriteriumCriterium · NCT05230810 · 40 enrolled · United States
  11. Feb 14, 2022Phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651 · 400 enrolled · United States, Argentina, Australia and more
  12. May 16, 2022Phase 1 study in Breast NeoplasmsPfizer · NCT05382364 · 25 enrolled · China
  13. Jun 27, 2022Phase 2 study in Breast NeoplasmsCriterium · NCT05458674 · 17 enrolled · United States
  14. Aug 12, 2026Phase 4 study in Uterine Cervical NeoplasmsPfizer · NCT07768358 · 175 planned

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Breast NeoplasmsPfizer · NCT05382364
  2. Jun 1, 2027Primary completion: phase 2 study in Breast NeoplasmsCriterium · NCT05458674
  3. Dec 31, 2027Primary completion: phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651
  4. Mar 13, 2032Primary completion: phase 4 study in Uterine Cervical NeoplasmsPfizer · NCT07768358

TargetBeta

ERBB2 →read by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07768358Uterine Cervical Neoplasms4Not yet recruitingPfizerMar 13, 2032175
NCT05458674Breast Neoplasms · United States2Active, not recruitingCriteriumJun 1, 202717
NCT05382364Breast Neoplasms · China1Active, not recruitingPfizerDec 31, 202625
NCT05253651Colorectal Neoplasms · United States, Argentina, Australia and more3Active, not recruitingPfizerDec 31, 2027400
NCT05230810HER2-positive Metastatic Breast Cancer · United States2Active, not recruitingCriteriumMar 30, 202640
NCT05132582Breast Neoplasms · United States, Australia, Austria and more3Active, not recruitingPfizerSep 5, 2025654
NCT04721977Breast Neoplasms · Japan, South Korea, Taiwan2Active, not recruitingPfizerJul 17, 202366
NCT04632992Advanced Unresectable or Metastatic Solid Malignancy · United States2CompletedHoffmann-La RocheDec 4, 2023252
NCT04579380Uterine Neoplasms · United States, Belgium, Germany and more2Active, not recruitingPfizerNov 1, 2023217
NCT04539938Breast Neoplasms · United States2CompletedPfizerJul 15, 202470
NCT04538742Breast Neoplasms · United States, Australia, Brazil and more2Active, not recruitingAstraZenecaJan 31, 2025245
NCT04499924Adenocarcinoma Of Esophagus · United States, Australia, Canada and more3CompletedPfizerApr 17, 202417
NCT04430738Colorectal Neoplasms · United States, Japan2Active, not recruitingPfizerJul 31, 202440
NCT03975647HER2-positive Breast Cancer · United States, Australia, Austria and more3Active, not recruitingPfizerJun 29, 2023466
NCT03914755Healthy · United States1CompletedPfizerAug 4, 201936
NCT03826602Drug-drug Interaction · United States1CompletedPfizerMar 8, 201918
NCT03777761Healthy · United States1CompletedPfizerMar 11, 201955
NCT03758339Healthy · United States1CompletedPfizerJan 30, 20188
NCT03723395Drug-drug Interaction · United States1CompletedPfizerDec 21, 2018116
NCT03722823Hepatic Impairment · United States1CompletedPfizerMay 7, 201937
NCT03043313Colorectal Neoplasms · United States, Belgium, France and more2CompletedPfizerMar 28, 2022117
NCT02614794Breast Neoplasms · United States, Australia, Austria and more2CompletedPfizerSep 4, 2019612
NCT02025192Breast Neoplasms · United States1CompletedPfizerOct 3, 201760
NCT01983501Breast Neoplasms · United States, Canada1CompletedPfizerOct 10, 201757
NCT00650572Neoplasms · United States, Canada1CompletedPfizerMar 201350

How it is read

Names in the registry

  • “Tucatinib”, 12 entries
  • “tucatinib”, 11 entries
  • “Tucatinib (ONT-380)”, 1 entry
  • “ARRY-380, HER2 inhibitor; oral”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.